{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:24:24Z","timestamp":1783527864111,"version":"3.55.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Azienda Ospedaliera Universitaria Federico II"},{"name":"University Federico II"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Cangrelor is approved for oral P2Y12 inhibitor na\u00efve patients undergoing percutaneous coronary intervention (PCI). Pharmacodynamic (PD) investigations in different clinical settings, using various assays, have shown contrasting data in terms of entity of platelet inhibition and rates of high residual platelet reactivity (HRPR). We assessed the PD effects in patients with or without ST elevation myocardial infarction (STEMI) receiving cangrelor during PCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The PharmacOdynaMic effects of cangrelor in PatiEnts wIth acute or chronIc coronary syndrome undergoing percutaneous coronary intervention (POMPEII) registry (NCT04790032) is an investigator-initiated, prospective study assessing PD at four time points with three assays. From March 2021 to June 2024, 126 patients na\u00efve from oral P2Y12 inhibitors underwent PCI with cangrelor [32 with STEMI and 94 without (NSTE-ACS = 30, CCS = 64)]. All STEMI patients switched from cangrelor to ticagrelor, while most patients without STEMI switched to clopidogrel. Inhibition of platelet aggregation (IPA%) during cangrelor infusion was lower in patients with STEMI compared with those without STEMI (LTA 20-\u03bcM-ADP 51.5 \u00b1 16.2% vs. 59.7 \u00b1 16.2%; P = 0.017). Conversely, after switching from cangrelor to an oral P2Y12 inhibitor, IPA was greater in patients with STEMI compared with those without STEMI. Rates of HRPR were consistent with lower platelet inhibition in STEMI during cangrelor and greater after its discontinuation compared with patients without STEMI. Within STEMI patients, cangrelor-induced IPA was lower compared with ticagrelor-induced IPA (P = 0.036).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cangrelor-induced platelet inhibition was lower in patients with STEMI compared with those without STEMI and was lower than that induced by ticagrelor among STEMI patients. The switch from cangrelor to an oral P2Y12 inhibitor exposed patients without STEMI to greater HRPR compared with those with STEMI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjacc\/zuag056","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T11:24:44Z","timestamp":1776079484000},"page":"524-534","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacodynamic effects of cangrelor in patients with or without STEMI undergoing percutaneous coronary intervention: insights from the POMPEII study"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4395-6742","authenticated-orcid":false,"given":"Giuseppe","family":"Gargiulo","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples , Via S. Pansini 5, Naples 80131 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviana","family":"Narciso","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples , Via S. Pansini 5, Naples 80131 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imma","family":"Forzano","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples , Via S. Pansini 5, Naples 80131 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Sperandeo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples , Via S. Pansini 5, Naples 80131 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico Simone","family":"Castiello","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples , Via S. Pansini 5, Naples 80131 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorenzo","family":"Simonetti","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples , Via S. Pansini 5, Naples 80131 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Manzi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples , Via S. Pansini 5, Naples 80131 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Florimonte","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples , Via S. Pansini 5, Naples 80131 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Enrico","family":"Canonico","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples , Via S. Pansini 5, Naples 80131 ,","place":["Italy"]},{"name":"CPC Clinical Research, University of Colorado , Aurora, CO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Avvedimento","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples , Via S. Pansini 5, Naples 80131 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5170-517X","authenticated-orcid":false,"given":"Roberta","family":"Paolillo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples , Via S. Pansini 5, Naples 80131 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Spinelli","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples , Via S. Pansini 5, Naples 80131 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Di Serafino","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples , Via S. Pansini 5, Naples 80131 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Anna Maria","family":"Spaccarotella","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples , Via S. Pansini 5, Naples 80131 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Franzone","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples , Via S. Pansini 5, Naples 80131 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3124-9912","authenticated-orcid":false,"given":"Raffaele","family":"Piccolo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples , Via S. Pansini 5, Naples 80131 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Stabile","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Azienda Ospedaliera Regionale \u2018San Carlo,\u2019 Potenza ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Plinio","family":"Cirillo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples , Via S. Pansini 5, Naples 80131 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[{"name":"Cardiocentro Institute, Ente Ospedaliero Cantonale, Universit\u00e0 Della Svizzera Italiana (USI) , Lugano ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0565-7127","authenticated-orcid":false,"given":"Giovanni","family":"Esposito","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University of Naples , Via S. Pansini 5, Naples 80131 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"2026070812121069500_zuag056-B1","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"2026070812121069500_zuag056-B2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/ehjcvp\/pvaf042","article-title":"The role of cangrelor in acute and high-risk PCI settings","volume":"11","author":"Zeymer","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026070812121069500_zuag056-B3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/14779072.2025.2544816","article-title":"Cangrelor in percutaneous coronary interventions: advances in evidence, clinical applications, and future directions","volume":"23","author":"De Sio","year":"2025","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2026070812121069500_zuag056-B4","first-page":"1266","article-title":"Pharmacodynamic effects of cangrelor in elective complex PCI: insights from the POMPEII registry","volume":"18","author":"Gargiulo","year":"2023","journal-title":"EuroIntervention"},{"key":"2026070812121069500_zuag056-B5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2459\/JCM.0000000000001737","article-title":"Dual antiplatelet therapy de-escalation by discontinuation in patients with ST-segment elevation myocardial infarction: a systematic review and meta-analysis","volume":"26","author":"Spagnolo","year":"2025","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2026070812121069500_zuag056-B6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2459\/JCM.0000000000001749","article-title":"Early DAPT de-escalation after STEMI: promise or premature?","volume":"26","author":"Castiello","year":"2025","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2026070812121069500_zuag056-B7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11239-012-0737-3","article-title":"Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials","volume":"34","author":"Angiolillo","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"2026070812121069500_zuag056-B8","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jacc.2018.07.041","article-title":"Cangrelor in ticagrelor-loaded STEMI patients undergoing primary percutaneous coronary intervention","volume":"72","author":"Alexopoulos","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026070812121069500_zuag056-B9","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.118.038317","article-title":"Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"139","author":"Franchi","year":"2019","journal-title":"Circulation"},{"key":"2026070812121069500_zuag056-B10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.120.046928","article-title":"Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment-elevation myocardial infarction: primary results of the FABOLUS-FASTER trial","volume":"142","author":"Gargiulo","year":"2020","journal-title":"Circulation"},{"key":"2026070812121069500_zuag056-B11","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"key":"2026070812121069500_zuag056-B12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jcin.2022.10.034","article-title":"Cangrelor in patients with coronary artery disease pretreated with ticagrelor: the switching antiplatelet (SWAP)-5 study","volume":"16","author":"Franchi","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"2026070812121069500_zuag056-B13","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1016\/j.jcin.2023.08.009","article-title":"Switching from cangrelor to prasugrel in patients undergoing percutaneous coronary intervention: the switching antiplatelet-6 (SWAP-6) study","volume":"16","author":"Franchi","year":"2023","journal-title":"JACC Cardiovasc Interv"},{"key":"2026070812121069500_zuag056-B14","doi-asserted-by":"crossref","first-page":"560","DOI":"10.4244\/EIJ-D-24-00757","article-title":"Pharmacodynamic effects of cangrelor in patients with acute or chronic coronary syndrome undergoing percutaneous coronary intervention: the POMPEII registry","volume":"21","author":"Gargiulo","year":"2025","journal-title":"EuroIntervention"},{"key":"2026070812121069500_zuag056-B15","first-page":"101344","article-title":"Cangrelor in contemporary patients with ST-segment elevation myocardial infarction pretreated with ticagrelor: pharmacodynamic data from the POMPEII study","volume":"50","author":"Gargiulo","year":"2024","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2026070812121069500_zuag056-B16","first-page":"475","article-title":"Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"5","author":"Capranzano","year":"2016","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026070812121069500_zuag056-B17","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"2026070812121069500_zuag056-B18","doi-asserted-by":"crossref","first-page":"e795","DOI":"10.1161\/CIRCULATIONAHA.120.050205","article-title":"Letter by angiolillo et al regarding article, \u201ccangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment-elevation myocardial infarction: primary results of the FABOLUS FASTER trial\u201d","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"key":"2026070812121069500_zuag056-B19","doi-asserted-by":"crossref","first-page":"e797","DOI":"10.1161\/CIRCULATIONAHA.120.051945","article-title":"Response by gargiulo et al to letter regarding article, \u201ccangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment-elevation myocardial infarction: primary results of the FABOLUS FASTER trial\u201d","volume":"143","author":"Gargiulo","year":"2021","journal-title":"Circulation"},{"key":"2026070812121069500_zuag056-B20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jcin.2021.11.016","article-title":"The effects of cangrelor on platelet aggregation in STEMI patients: methodological or pharmacological issues?","volume":"15","author":"Landi","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"2026070812121069500_zuag056-B21","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1016\/j.jcin.2021.07.051","article-title":"Impact of timing of pharmacodynamic assessment on platelet reactivity in patients treated with cangrelor","volume":"14","author":"Franchi","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"2026070812121069500_zuag056-B22","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jcin.2021.12.002","article-title":"Reply: the effects of cangrelor on platelet aggregation in STEMI patients: methodological or pharmacological issues?","volume":"15","author":"Franchi","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"2026070812121069500_zuag056-B23","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1586\/erc.09.101","article-title":"Cangrelor: a review on its mechanism of action and clinical development","volume":"7","author":"Ferreiro","year":"2009","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"2026070812121069500_zuag056-B24","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(24)01616-7","article-title":"De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials","volume":"404","author":"Valgimigli","year":"2024","journal-title":"Lancet"}],"container-title":["European Heart Journal: Acute Cardiovascular Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjacc\/advance-article-pdf\/doi\/10.1093\/ehjacc\/zuag056\/68083855\/zuag056.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/15\/7\/524\/68083855\/zuag056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjacc\/article-pdf\/15\/7\/524\/68083855\/zuag056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:12:20Z","timestamp":1783527140000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjacc\/article\/15\/7\/524\/8654148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,4,15]]},"published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjacc\/zuag056","relation":{},"ISSN":["2048-8726","2048-8734"],"issn-type":[{"value":"2048-8726","type":"print"},{"value":"2048-8734","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,4,15]]}}}